Compare Novavax Inc (NVAX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Novavax Inc trades at $12.57 (market cap $1.82B), while Vanguard Information Technology Index Fund ETF trades at $127.64 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 93.5× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 5,132,883). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| NVAX | VGT | |
|---|---|---|
Market Cap | $1.82B | $170.20B |
Volume | 6,198,505 | 5,132,883 |
Sector | Health | — |
52-Week High | $12.56 | $129.79 |
52-Week Low | $6.22 | $83.59 |
Typical Hold Time | 59 Days | 129 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
VGT trades at $127.00, down 1.83% today but maintains a bullish technical outlook with strong moving average support. The ETF's focus on pure-play technology stocks like Nvidia, Apple, and Microsoft has delivered exceptional historical returns, averaging over 17% annually for two decades according to The Motley Fool (2026-10-03). Recent institutional buying activity signals continued confidence in the tech sector's growth prospects.
While VGT offers concentrated tech exposure with low fees, investors face sector concentration risk and potential AI slowdown concerns. The ETF's exclusion of major tech names like Google and Amazon due to classification rules creates unexpected portfolio gaps. Current technical strength supports near-term upside, but macroeconomic headwinds could pressure tech valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
